Table 4.
Prognostic significance of the expression of glypicans on the relapse-free survival of breast cancer patients stratified by HER2 status
| Genes | HER2 status | Relapse free survival | ||
|---|---|---|---|---|
| Number of cases | HR 95% CI | P value | ||
| GPC1 | Positive | 252 | 1.51 (0.97–2.35) | 0.063 |
| Negative | 800 | 1.08 (0.83–1.4) | 0.58 | |
| GPC2 | Positive | 150 | 0.79 (0.46–1.37) | 0.41 |
| Negative | 635 | 0.89 (0.66–1.2) | 0.44 | |
| GPC3 | Positive | 252 | 0.78 (0.51–1.21) | 0.27 |
| Negative | 800 | 0.85 (0.66–1.11) | 0.24 | |
| GPC4 | Positive | 252 | 1.44 (0.93–2.23) | 0.099 |
| Negative | 800 | 0.86 (0.66–1.12) | 0.27 | |
| GPC5 | Positive | 252 | 0.76 (0.49–1.18) | 0.22 |
| Negative | 800 | 0.99 (0.76–1.29) | 0.95 | |
| GPC6 | Positive | 150 | 1.11 (0.64–1.9) | 0.72 |
| Negative | 635 | 1.45 (1.08–1.96) | 0.014 | |
Bold typing of P values indicates a significance level P < 0.05
HR Hazard ratio, CI confidence interval